{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-010227","form_type":"8-K","ticker":"IMA","cik":"0001835579","company_name":"ImageneBio, Inc.","filed_at":"2024-01-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.861642+00:00","generated_at":"2026-06-06T22:04:13.896976+00:00","sec_items":["2.02","2.05","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ikena Oncology cuts workforce 35%, focuses on IK-930/595; BMS declines opt-in on two programs","bullets":["Workforce reduction of ~35% (approx. 20 employees) to focus on clinical programs IK-930 and IK-595.","Cash, cash equivalents and marketable securities ~$175M as of Dec 31, 2023 (unaudited); runway extended into 2H 2026.","Bristol Myers Squibb declined opt-in for IK-175 program; also did not opt-in for IK-412; full rights returned to Ikena.","IK-930 optimized formulation now in clinic; clinical data update planned for 2H 2024.","IK-595 first cohort dosed and cleared safety evaluation window; enrollment in RAS/RAF mutant patients ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-010227","json":"https://secwatch.observer/filing/0001193125-24-010227.json","markdown":"https://secwatch.observer/filing/0001193125-24-010227.md","text":"https://secwatch.observer/filing/0001193125-24-010227.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835579/000119312524010227/0001193125-24-010227-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835579/000119312524010227/d459979d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T22:04:13.896976+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e293c194c1c90d16dd23ebae95d6a49612eb4c88","claim":"ImageneBio, Inc. announced a restructuring with charges of approximately $1.6 million affecting discovery organization, as well as select employees working in development and general and administrative functions (approximately 35%).","evidence_excerpt":"to the discontinuation of its discovery efforts and expects to recognize these charges during the three months ended March 31, 2024, of which aggregate charges of approximately $1.6 million relate to the Workforce Reduction. Expenses related to the Workforce Reduction consist of employee severance and related termination benefits, and are expected to result in","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835579/000119312524010227/0001193125-24-010227-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $1.6 million"},{"label":"Affected area","value":"discovery organization, as well as select employees working in development and general and administrative functions"},{"label":"Headcount","value":"approximately 35%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}